Durvalumab in the treatment of non‑small cell lung cancer

01/2020 Special Edition

MUDr. Ondřej Bílek

Klinika komplexní onkologické péče, MOÚ, Brno



Lung cancer represents the leading cause of cancer death worldwide. Most of the patients are diagnosed with advanced disease. Targeting immune-checkpoint inhibitors represents a standard option for advanced non-small cell lung cancer. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in advanced NSCLC.


Key words

non-small cell lung cancer, chemo-radiation therapy, immunotherapy, durvalumab



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...